CGC Genomics funding news – Basel-based CGC Genomics Secures €1.7 Million in Pre-Seed Funding

The funding round was backed by Heal Capital, Becker Ventures, Springboard Health Angels, Superangels, and better ventures, along with angel investors Christoph Behn, Nicolas Weber, and Helmut Deschauer.

James Creeden, MD PhD, Co-CEO of CGC Genomics and former Chief Medical Officer at Roche & Foundation Medicine said, “With Qnomx, we are building regulatory-compliant GenAI – enabling more precise therapies with less burden on medical professionals,”.

CGC Genomics plans to launch Qnomx as the first generative AI tool for cancer diagnosis that meets official regulations, including IVDR, MDR, and the European AI Act.

It’s being built under a certified quality system (ISO 13485) and provides a clear, trackable alternative to unregulated tools like ChatGPT, which some clinics are already using.

Christian Lautner, Founding Managing Partner of Heal Capital said, “With Qnomx, we’re supporting visionary founders building the AI infrastructure for the future of precision medicine. Qnomx impresses with an experienced team and a groundbreaking approach to one of the field’s core challenges: making genomic data truly actionable. We’re confident they will set a new standard for the safe use of generative AI in clinical diagnostics and therapy,”.

Cancer cases are rising worldwide — in 2022, over 20 million new cases were reported. Targeted treatments now often depend on advanced tests like Next Generation Sequencing (NGS) to analyze tumors.

But only 20–30% of patients who should get these tests actually do. That’s because about 80% of doctors say NGS reports are too complex and hard to understand quickly, making it tough to choose the right treatment without expert help.

Marc Becker, Managing Director of Labor Becker MVZ eGbR said, “We’re excited to announce our collaboration with CGC Genomics. As one of Bavaria’s leading laboratory medicine companies, with over 650 employees across 12 locations, we are committed to continuous innovation to provide our healthcare partners with top-tier diagnostics and streamlined processes. Based on our expertise in molecular pathology and genetic testing we see significant potential in CGC Genomics’ Qnomx platform to further optimize the interpretation of complex genomic data. This partnership allows us to increase the efficiency and quality of our NGS process and make a valuable contribution to precision medicine. We are confident this collaboration will advance diagnostics and look forward to the next steps with CGC Genomics,”.

Early use of the tool has shown it saves a lot of time. It's now being tested in pilot projects with Labor Becker and the OnkoMedeor Group. Instead of spending up to two hours on manual analysis, Qnomx can give a clear summary of important results in just minutes — in the local language and always checked by a human expert.

Read also - EcoDataCenter funding news – EcoDataCenter Secures €450 Million in Funding

Dr Joerg Hoelzing, Co-CEO of CGC Genomics said, “Diagnostics can scale – interpretation cannot. That’s exactly what we’re changing with Qnomx,”.

Tina Dreimann, Founder and managing director of better ventures said, “Artificial intelligence will fundamentally transform healthcare – but only if it is regulated, explainable, and responsibly applied. That is exactly what CGC Genomics delivers: a team with deep medical expertise, a clear vision, and a product that is safe for patients, scalable, and economically viable. Qnomx democratises access to precision cancer therapy – bringing cutting-edge medicine to where expertise is currently lacking,”.

About CGC Genomics

CGC Genomics is changing how cancer genome data is understood to help choose better treatments. Their QNOMX platform helps labs automate the final review of genetic reports, making the testing process faster, more efficient, and less expensive. This helps doctors make quicker and better treatment decisions.